Gladius Pharmaceuticals

Gladius Pharmaceuticals was a Canadian private biopharmaceutical company focused on developing novel antibiotics for life-threatening Gram-negative and multidrug-resistant bacterial infections. Its lead disclosed program, GL-332, was described as a once-daily cephalosporin designed for empiric treatment and activity against difficult Gram-negative pathogens including multidrug-resistant Pseudomonas aeruginosa. The company was also described as a platform-based antibiotic developer built around modified beta-lactam chemistry invented by founder Larry Sutton. Public business databases indicate the company was founded in 2015, raised venture funding, and later became out of business.